Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma

NCT03294954 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT03294954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03294954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
January 18, 2018
Completion date
August 10, 2040
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma